Current Edition


Recent FDA Advancements in Rare Diseases – Funding, Partnerships, and Programs

The paucity of therapeutic choices is a reality often acknowledged by the US Food and Drug Administration (FDA) as it reviews applications for new medical …

Continue Reading →
Alnylam Pharmaceuticals

Watch out, Pfizer and Alnylam. AstraZeneca wades deeper into rare diseases with Ionis tie-up

Just months after wrapping up the Alexion acquisition, AstraZeneca is beefing up its newly established rare disease portfolio with a collaboration with Ionis Pharmaceuticals, targeting …

Continue Reading →

Ipsen poaches Novartis vet Scheiffele to serve as president of its international specialty care team

Amid its push to grow around the globe in oncology, rare diseases and neuroscience, Ipsen has poached a Novartis veteran to head up its international …

Continue Reading →